Government of Switzerland   Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2017
NCT02972450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Empa, Swiss Federal Laboratories for Materials Science and Technology | Empa - Swiss Federal Laboratories for Materials Testing and Research, Zürich | Innosuisse | State Secretariat for Education Research and Innovation, Switzerland | Swiss Agency for Development and Cooperation (SDC) | Swiss Armed Forces | Swiss Government

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Spinal Cord Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 9